TOP HEADLINES

Featured Story

  • Pfizer continues to explore virtual trials with 23andMe pact

    Pfizer and 23andMe have teamed up to identify genetic factors linked to inflammatory bowel disease. And with 23andMe trumpeting the fact that people can participate without leaving their homes, the study represents a continuation of Pfizer's interest in virtual trials.

Clinverse and Comprehend raise $30M in separate financing rounds

Clinverse and Comprehend have raised a total of $30.1 million in separate Series C and B financing rounds, giving both companies the cash to push ahead with their expansion plans.

Rock Health backs cloud-based R&D platform as Abbott comes on board

Digital health investor Rock Health has added 8 startups to its portfolio, bringing the number of active companies in its network up to 55. And with one of the startups focusing on life science R&D and Abbott among its new corporate partners, the incubator has strengthened its ties to drug development.

Survey: Scientists talk on Twitter, network on ResearchGate

With scholarly social network ResearchGate now adding 10,000 users a day to its network of 4.5 million researchers, the idea of a "Facebook for science" has finally taken off. But these numbers say nothing about whether people actually use the site and why, a shortcoming Nature has tried to fix by surveying thousands of researchers about their social media habits.

Oxford Nanopore raises $59M to scale up production of MinION sequencer

With Oxford Nanopore's oversubscribed offering pulling in $59 million (£35 million), the British startup has the money to scale up production of its sequencer while developing new uses for the underlying technology.

Intel to apply wearables, cloud storage and analytics to Parkinson's research

Intel has spent the past year adding tools for gathering and analyzing data, notably by taking a stake in Cloudera and buying Basis. And the strategy now has a major test case, with the Michael J. Fox Foundation teaming up with Intel to remotely monitor people with Parkinson's disease.

MORE NEWS

From Our Sister Sites

FierceAnimalHealth

MSD Animal Health, known as Merck Animal Health in the U.S. and Canada, released a new fish vaccine on Aug. 18 that is intended to protect tilapia from a dangerous strain of Streptococcus agalactiae. Tilapia, a popular farmed food fish feeding a global demand, is especially vulnerable to the strain of strep in Thailand and Malaysia.

FierceAnimalHealth

Kinavet CA-1 drew FDA ire last month for bogus marketing claims, but the canine cancer drug, intended to treat mast cell tumors, has gone ahead to a Phase III clinical trial in Florida.